Cutaneous reactions to non-steroidal anti-inflammatory drugs

Journal of Drugs in Dermatology

Volumn 10, Issue 10, 2011, Pages 1160-1167

  Kasemsarn, Pranee ^a   Kulthanan, Kanokvalai ^a   Tuchinda, Papapit ^a   Dhana, Naruemon ^a   Jongjarearnprasert, Kowit ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; DIPYRONE; IBUPROFEN; INDOMETACIN; LOXOPROFEN; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; TENOXICAM; VALDECOXIB;

ADULT; AGED; ANGIONEUROTIC EDEMA; DRESS SYNDROME; DRUG ERUPTION; DRUG USE; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FEMALE; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; OSTEOARTHRITIS; RETROSPECTIVE STUDY; REVIEW; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; URTICARIA; YOUNG ADULT;

EID: 80054767738     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Adkinson NF, Yunginger JW, Busse WW, eds. Middleton's Allergy: Principles and Practice. 6th ed. St. Louis: Mosby; 2003:1695-1710.
2. Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol. 2009;44 Suppl 19:72-76.
3. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004;31(Suppl 7):12-21. (Pubitemid 38879410)
4. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002;23(Suppl):S35-40. (Pubitemid 34461953)
5. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-32. (Pubitemid 26324038)
6. Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-21. (Pubitemid 33144916)
7. Woodbury DM, Fingl E. Analgesic-antipyretics, antiinflammatory agents and drugs employed in the therapy of gout. In: Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. New York: Macmillan; 1975.
8. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.
9. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307-314. (Pubitemid 29089366)
10. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther. 2005;12:46-55. (Pubitemid 40516046)
11. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol. 2003;24:125-136.
12. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 1999;48:839-846.
13. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977;60:276-284. (Pubitemid 8225955)
14. Okazaki T, Ilea VS, Rosario NA, et al. Regulatory role of prostaglandin E in allergic histamine release with observations on the responsiveness of basophil leukocytes and the effect of acetylsalicylic acid. J Allergy Clin Immunol. 1977;60:360-366. (Pubitemid 8247352)
15. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol. 2002;3:599-607. (Pubitemid 36009055)
16. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983;74:102-109. (Pubitemid 13100788)
17. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84:101-106. (Pubitemid 30082865)
18. Capriles-Behrens E, Caplin J, Sanchez-Borges M. NSAID facial angioedema in a selected pediatric atopic population. J Investig Allergol Clin Immunol. 2000;10:277-279.
19. Strom BL, Carson JL, Morse ML, et al. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1987;30:1142-1148. (Pubitemid 18027302)
20. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74:430.
21. Puavilai S, Noppakun N, Sitakalin C, et al. Drug eruptions at five institutes in Bangkok. J Med Assoc Thai. 2005;88:1642-1650. (Pubitemid 44698982)
22. Bigby M, Stern R. Cutaneous reactions to nonsteroidal anti-inflammatory drugs: a review. J Am Acad Dermatol. 1985;12:866-876. (Pubitemid 15052483)
23. World Health Organization. Causality Assessment of Suspected Adverse Reactions. Available at: http://www.who-umc.org/. Accessed January 31, 2010.
24. Vervloet D, Pradal M, Castelain M. Drug allergy. Uppsala: Pharmacia & Upjohn; 1999.
25. Schubert B, Grosse Perdekamp MT, Pfeuffer P, et al. Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol. 2005;15:164-167. (Pubitemid 40733422)
26. Hassani A, Ponvert C, Karila C, et al. Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases. Eur J Dermatol. 2008;18:561-565.
27. Isik SR, Karakaya G, Celikel S, et al. Association between asthma, rhinitis and NSAID hypersensitivity in chronic urticaria patients and prevalence rates. Int Arch Allergy Immunol. 2009;150:299-306.
28. Vichyanond P, Sunthornchart S, Singhirannusorn V, et al. Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. Respir Med. 2002;96:34-38. (Pubitemid 41122768)
29. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87:177-180. (Pubitemid 32879888)
30. Asero R. Predictive value of autologous plasma skin test for multiple nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol. 2007;144:226-230. (Pubitemid 47587609)
31. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442. (Pubitemid 32747607)
32. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87: 201-204. (Pubitemid 32879892)
33. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Adverse reactions to selective cyclooxygenase-2 inhibitors (coxibs). Am J Ther. 2004;11:494-500.
34. Verbeiren S, Morant C, Charlanne H, et al. Celecoxib induced toxiderma with positive patch-test. Ann Dermatol Venereol. 2002;129: 203-205. (Pubitemid 34263083)
35. Atzori L, Pinna AL, Pau M, et al. Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. J Cutan Med Surg. 2006;10:31-35. (Pubitemid 351506627)
36. Schneider F, Meziani F, Chartier C, et al. Fatal allergic vasculitis associated with celecoxib. Lancet. 2002;359:852-853. (Pubitemid 34233760)
37. Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696. (Pubitemid 44175039)
38. Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy. 2002;22:637-640. (Pubitemid 34464951)
39. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924. (Pubitemid 41428548)
40. Friedman B, Orlet HK, Still JM, Law E. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J. 2002;95:1213-1214. (Pubitemid 35244846)
41. Greenberger P, Patterson R, Kelly J, et al. Administration of radiographic contrast media in high-risk patients. Invest Radiol. 1980;15(Suppl):S40-3. (Pubitemid 11172937)
42. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy. 2003;23:551-553. (Pubitemid 36384336)
43. Fye KH, Crowley E, Berger TG, et al. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol. 2001;45:300-302. (Pubitemid 32729318)
44. Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology. 2004;209:53-56. (Pubitemid 39179107)
45. Bandyopadhyay D. Celecoxib-induced fixed drug eruption. Clin Exp Dermatol. 2003;28:452.
46. Yazici AC, Baz K, Ikizoglu G, et al. Celecoxib-induced photoallergic drug eruption. Int J Dermatol. 2004;43:459-461. (Pubitemid 38868258)